Leslie Eiland, MD, describes the importance of learning from the COVID-19 pandemic when it comes to ensuring continuous care for those with type 1 diabetes (T1D) during future pandemics.
We have a lot to learn when it comes to providing continuous care to vulnerable patients with type 1 diabetes in rural America during a health crisis, said Leslie Eiland, MD, an endocrinologist at the University of Nebraska Medical Center in Omaha, Nebraska.
Transcript:
How can the United States better prepare for the next pandemic with regard to ensuring a seamless continuation of care to vulnerable populations in rural areas?
I think we have a lot to learn and I think it's very important to reflect on this last year and figure out what went well and what did not go well. I do feel like, I think audio-only visits are something that have been discussed and are being debated in terms of whether they should be covered. I don't particularly enjoy doing audio-only visits or phone calls with my patients. But I have found that they have been needed over this last year, when in the spring, when our clinic was just not seeing anyone in-person, an in-person visit wasn't even an option. But then during other peak COVID-19 times or winter weather when my elderly patients didn't have to drive to the visit. I do think continuing to allow audio-only visits [is] important.
Another thing that my patients have struggled with is when they have a piece of diabetes technology covered by CMS, and they need to be seen at these regular intervals, like every 3 months. The phone visits have also been very helpful. When we weren't seeing people in clinic or when the weather is bad patients can get, my parents get very stressed out about needing to have this visit at a certain increment, otherwise they're not going to get their insulin pump or sensor supplies until after their visit, and they're going to run out and that's dangerous. So continuing to have these audio-only visits is an option I think is important.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More